stockrow
Saturday 7 November 2026
Export VALN’s income statement to Excel — free account
Valneva SE Sponsored ADR
VALN Healthcare Biotechnology
Valneva SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $197.6 million, up 7.69% from fiscal 2024.
- Revenue
- −17.3%
- EPS
- −222.1%
- Free cash flow
- −56.1%
- Total debt
- +12.1%
Quarter to June 2026, against a year earlier
5.57
0.07
−1.24%
Follow VALN
Alert me
Valneva SE Sponsored ADR (VALN) P/E ratio
As of 6 November 2026, Valneva SE Sponsored ADR (VALN) trades at a P/E ratio of 59.3×. Over the past ten years it has ranged from 0.0× (March 2024) to 75.9× (August 2026); the current reading is higher than 94% of that period. That is above the Biotechnology industry median of 10.6× and above the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 23.0× | 22.91% |
| FY2024 | 18.7× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 66.5× | 280.11% |
| Mar 2025 | 17.5× | (46.79%) |
| Mar 2024 | 32.9× | — |
| Sep 2023 | 0.0× | — |
| 14 more quarters | Free account |
Against its own ten years
Low 0.0×
High 75.9×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NGNE Neurogene Inc. compare | n/m |
| BCAX Bicara Therapeutics Inc. compare | n/m |
| FTH Faeth Therapeutics, Inc. compare | n/m |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR compare | n/m |
| ENTX Entera Bio Ltd. compare | n/m |
| ACRS Aclaris Therapeutics, Inc. compare | n/m |
| CLYM Climb Bio, Inc. compare | n/m |
| VALN Valneva SE Sponsored ADR | 59.3× |
| IAM Iambic Therapeutics, Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)